<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147510</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-GEN-CT4-10-095</org_study_id>
    <secondary_id>A070001</secondary_id>
    <nct_id>NCT01147510</nct_id>
  </id_info>
  <brief_title>Asthma Control in Elderly Patients With Montelukast</brief_title>
  <acronym>ACEM</acronym>
  <official_title>A Randomized Controlled Study of Montelukast Plus Low Dose Inhaled Budesonide Versus Medium Dose Inhaled Budesonide on Asthma Control in Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of combination therapy of montelukast plus low dose inhaled
      budesonide and single therapy of medium dose inhaled budesonide on asthma control such as
      inflammatory markers and clinical indicators and to compare treatment response according to
      leukotriene related genotypes in elderly patients with asthma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients reaching &quot;well controlled asthma status&quot;</measure>
    <time_frame>12-weeks treatment</time_frame>
    <description>Rate of patients reaching &quot;well controlled asthma status&quot; after 12-week treatment : evaluating comprehensively frequency of day symptoms and night symptoms, limit of activities and use of rescue medicine based on GINA guideline for asthma management (GINA 2006) and PEF or FEV1(% predicted)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of inflammation</measure>
    <time_frame>baseline(W1), W5, W9, W13, W17</time_frame>
    <description>sputum eosinophils and neutrophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first well-controlled week</measure>
    <time_frame>during the 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-group analysis of leukotrienes associated genotypes</measure>
    <time_frame>visit 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Persistent Asthma</condition>
  <condition>Elderly</condition>
  <arm_group>
    <arm_group_label>Monotherapy of medium dose ICS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of low ICS and montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of low ICS and montelukast</intervention_name>
    <description>Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.</description>
    <arm_group_label>Combination of low ICS and montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monotherapy of medium dose ICS</intervention_name>
    <description>Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day</description>
    <arm_group_label>Monotherapy of medium dose ICS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 60 - 75 years

          -  Patients diagnosed with asthma (NIH, 2007) over six months ago

          -  Patients maintaining monotherapy of low dose inhaled budesonide (pulmicort 400µg/day
             or ciclesonide 160 µg/day or fluticasone 250 µg/day) or combination of low dose
             inhaled budesonide and LABA (Seretide® 250 µg/day or Symbicort® 320 µg/day ) for over
             a month before the participation in this trial

          -  Patients not reaching 'well controlled asthma status' with four-week monotherapy of
             low dose inhaled budesonide (Pulmicort 400 µg/day)

          -  Patients who sufficiently listen to the purpose and content of this trial and the
             properties of investigational products and voluntarily agree with the participation to
             sign a written consent approved by IRB of Ajou University Medical Center before the
             participation in this trial

        Exclusion Criteria:

          -  Patients who show a symptom of an acute disease within 28 days before the beginning of
             this trial (administration of trial medication)

          -  Volunteers who are found to be unsuitable through screening tests

          -  Patients with history of hypersensitivity to montelukast or budesonide

          -  Patients participating in other clinical trial within three months before the
             beginning of this trial (administration of trial medication)

          -  current smokers having more than 10PYs of smoking history

          -  Patients needing administration of a medication which can affect asthma control such
             as systemic and immunoregulatory drugs (cyclosporin, omalizumab, etc.) due to a
             disease except asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hae-Sim Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou University Medical Center</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2010</study_first_submitted>
  <study_first_submitted_qc>June 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>November 10, 2013</last_update_submitted>
  <last_update_submitted_qc>November 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hae-Sim Park</investigator_full_name>
    <investigator_title>Professor, Department of allergy part, Ajou University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>asthma control in elderly patients</keyword>
  <keyword>age 60-75</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 26, 2014</submitted>
    <returned>April 8, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

